Longevity Biotech Inc is a preclinical biotechnology company focused on developing novel therapeutics utilizing a proprietary 'protein-like' molecular scaffold. Through the specific incorporation of non-natural amino acids, the Hybridtide scaffold affords several key advantages, specifically structural and digestive stability, while retaining biologic activity. These advantages uniquely allow Longevity to pursue the so-called 'undruggable' drug targets. While initial development efforts are focused primarily on capital-efficient orphan diseases, the scaffold can be applied to almost any active biological compound. Longevity has identified several high-value initial therapeutic areas where this breakthrough technology could address significant unmet medical needs via novel mechanisms of action and the company is actively pursuing these opportunities. The firm's focus is on developing specific modulators of pathways in order to leverage the bodyâs natural processes. One development - Hybridtide molecules - are targeted biologic-like molecules which are highly-resistant to breakdown by natural digestive enzymes and tunable to very stable molecular structures. Other research projects in the firm's pipeline including: GLP1/GIP dual agonist; Neuroprotection agent; HIV fusion inhibitor; and Cholesterol target
